A method of monitoring detection of an analyte in a liquid sample using a measuring cell, the measuring cell comprising a working electrode for excitation of electrochemiluminescence in the liquid sample, an optical detector for detecting the excited electrochemiluminescence, the excitation and detection being performed in an measurement cycle, the measurement cycle comprising transporting the liquid sample via a transport path to the working electrode using a support liquid, the method comprising: coupling light of a light source into the transport path during part of the measurement cycle, the transport path forming a light guide between the light source and the optical detector, detecting the coupled light by the optical detector, analyzing the detected light for a gas bubble in the transport path, providing a measurement state if the result of the analysis deviates from a target state regarding the presence of a gas bubble in the transport path.

This system takes in raw cellular material collected using a provided swab, blood collection device, urine collection device, or other sample collection device and transforms that biological material into a digital result, identifying the presence, absence and/or quantity of nucleic acids, proteins, and/or other molecules of interest.

The invention relates to methods for conducting binding assays in an assay device that includes one or more storage and use zone. The storage zones of the assay device are configured to house one or more reagents used in an assay conducted in the use zone of the device.

The present disclosure provides compositions, reagents, kits, systems, system components, and methods for performing assays. More particularly, the disclosure relates to an assay composition for detecting luminescence, which comprises an alkyl diethanolamine, for example, N-butyldiethanolamine (BDEA). In embodiments, the assay composition comprises 2-dibutylaminoethanol (BDAE).

The invention relates to novel compositions comprising an electrochemiluminescence (ECL) co-reactant. In embodiments, the composition further comprises an ionic component, a surfactant, or combination thereof. In embodiments, the ECL co-reactant is triethanolamine (TEA), tert-butyldiethanolamine (tBDEA), methyldibutylethanolamine (MDEA), 3-[Bis-(2-hydroxy-ethyl)-amino]-propane-1-sulfonic acid (DEA-PS), or a combination thereof. Methods of using the compositions and kits comprising the compositions are also provided herein.

The present invention relates to a biomolecule detection apparatus capable of easily and quickly detecting various biomolecules associated with diseases and determining the presence or absence of a specific disease. The biomolecule detection apparatus of the present invention includes a micropore device, a microchip, and sensing electrodes. According to the present invention, a microscale pore is formed inside the micropore device. In addition, the microchip is configured to pass through the microscale pore along the flow of a conductive liquid supplied inside the micropore device, has a surface coated with a sensing molecule complementarily bound to a target biomolecule, and has a unique code for identifying the complementarily bound target biomolecule. The sensing electrodes serve to sense the code by measuring change in current flowing through the pore when the microchip passes through the pore.

Disclosed herein are particles and methods of using said particles in assays for detection of biomolecules in a sample. Various methods of the present disclosure utilize particles for biomolecule adsorption. In some aspects, the present disclosure provides methods which utilize multiple particle concentrations to differentially fractionate biological samples. In further aspects, the present disclosure provides methods which utilize low particle concentrations to enhance adsorbed biomolecule diversity.

Improved surface enhanced Raman spectroscopy (SERS) of biological targets in liquids is provided. Nanoparticles are treated with a surfactant to provide an electrostatic attraction between the nanoparticles and the biological targets. The resulting clustering of the nanoparticles at the biological targets improves the SERS signal, Such SERS spectroscopy enables real time monitoring of the biological targets, thereby enabling a wide variety of assays etc.

The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

The invention relates to the use of disconnection agents before, or together with, toxic agents for the treatment of solid tumours.